Veerhealth Care Reports Strong H1FY27 Growth and USFDA Clearance
Veerhealth Care Ltd · Press Release · 16 Nov 2026, 10:28 pm
Veerhealth Care Reports Strong H1FY27 Growth and USFDA Clearance Veerhealth Care reported robust H1FY27 standalone results with revenue from operations surging 458.21% YoY to ₹47.28 crore, EBITDA rising 200.73% YoY to ₹4.12 crore, and net profit up 397.96% YoY to ₹2.44 crore. FY27 guidance projects total income of ₹105 crore with PAT of ₹5-7 crore, expanding to ₹156 crore and PAT of ₹9-11 crore in FY28. Growth catalysts include USFDA clearance for OTC drug exports to the US, key export order wins, entry into Russia, and expanded domestic e-commerce distribution across major platforms.
Original exchange filing (PDF)
More announcements from Veerhealth Care Ltd
- Please find the attached unaudited financial results along with the limited review report for half year ended September, 2026 · 14 Nov 2026
- Please find the attached herewith outcome of the board meeting approving the financial results for half year ended 30/09/2026 · 14 Nov 2026
- Veerhealth Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve 1. To consider and approve .... · 14 Nov 2026
- Submission of the transcript of Investors'' call held on 24th October, 2026 · 28 Oct 2026
- Outcome of the investors'' meeting under Reg 30 of LODR held on 24.10.2026 · 27 Oct 2026
- Submission of the link of video recording of investors'' call. · 27 Oct 2026
- Please find attach herewith intimation of investor call scheduled to be held on 24.10.2026 at 03.00 p.m. · 19 Oct 2026
- The Company wishes to inform that it has received an order for supply of skin care products from one of the India''s largest FMCG Company for a value of Rs. 454.68 Lakhs · 03 Oct 2026
